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Abstract
Background: The transcription factor sex-determining region Y-box protein 3 (SOX3) plays important roles in
various types of cancer. However, its expression and function have not yet been elucidated in osteosarcoma (OS).
Methods: The expression levels of SOX3 in OS tissues and OS cell lines were determined by quantitative real-time
polymerase chain reaction (qRT-PCR) and Western blot analysis. The effects of SOX3 expression on OS cell
biological traits were investigated by overexpressing and downregulating SOX3 protein. The expression of
epithelial-mesenchymal transition (EMT) markers and transcription factors associated with EMT (EMT-TFs), were
detected simultaneously. The mechanism underlying SOX3-mediated Snail1 expression was further investigated.
Results: SOX3 was upregulated in human OS tissues. SOX3 overexpression promoted the EMT, migration and invasion
in OS cells. The downregulation of SOX3 resulted in opposing effects. Furthermore, SOX3 upregulation enhanced the
expression of the transcriptional repressor Snail1 by binding to its promoter region. Additionally, a positive correlation
among the expression of SOX3, Snail1, and E-cadherin was demonstrated in human OS tissues.
Conclusions: SOX3 promotes migration, invasiveness, and EMT in OS cells via transcriptional activation of Snail1
expression, suggesting that SOX3 is a novel regulator of EMT in OS and may serve as a therapeutic target for the
treatment of OS metastasis.
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Background
Osteosarcoma (OS) is one of the most prevalent malig-
nant bone tumors in childhood and adolescence. Similar
to most other malignant tumors, OS is characterized by
a high propensity for metastasis, which is the leading
cause of death [1]. Despite several advancements in
neoadjuvant chemotherapies and surgical methods in
the treatment of OS, the 5-year survival of patients with
metastatic disease is dismal (<20%) [2–4]. Therefore, it
is necessary to urgently identify new targets or factors
that govern metastasis and to develop novel therapeutic
strategies for OS management.
Epithelial to mesenchymal transition (EMT), a devel-
opmental process in which epithelial cells lose polarity
and develop a mesenchymal phenotype, plays an import-
ant role in the initiation of metastasis [5]. It is believed
that EMT endows cancer cells with migratory and
invasive properties, and induces cancer stem cell (CSC)
properties [6]. The complex genetic changes during
EMT are, at least in part, mediated by a number of spe-
cific transcription factors, such as Snail, Slug, Twist1,
ZEB1, and ZEB2 [7–9]. Snail is overexpressed in various
human solid tumors, including numerous types of
carcinomas, as well as sarcomas, gliomas, neuroblasto-
mas, and melanomas [10, 11]. Further, increased Snail1
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expression in cancer cells promotes metastatic ability in
vivo, as well as cell survival, angiogenesis, and chemore-
sistance in vitro [12–14]. In addition, exogenous overex-
pression of Snail1 increases the invasive and metastatic
abilities of cancer cells through promoting the downreg-
ulation of E-cadherin and EMT [15]. However, the mo-
lecular mechanism underlying the upregulation of Snail1
in cancer cells remains unclear.
Sex-determining region Y-box protein 3 (SOX3) is a
member of the Sox family of transcription factors that
plays an important role in developmental processes, in-
cluding neurogenesis [16], testis development [17], and
chondrogenesis [18], among others [19, 20]. The expres-
sion of SOX3 decreases as development proceeds, and
correlates with the cellular switch from proliferation to
differentiation [21]. Recent studies have reported that
SOX3 is upregulated in cancer tissues and may therefore
play an oncogenic role in esophageal squamous cell car-
cinoma, ovarian cancer, and T-cell lymphomas [22–24].
Aberrant SOX3 expression also induces oncogenic
transformation of chicken embryonic fibroblasts [25].
However, the function of SOX3 in OS progression has
not yet been investigated.
In the present study, we first demonstrate that SOX3
expression is upregulated in human OS tissues and
promotes metastatic potential both in vitro and in vivo.
SOX3 also induces EMT via enhancing Snail1 expression
in OS cells. Moreover, we reveal a positive correlation
between SOX3 and Snail1 expression in OS samples.
Methods
Tissue specimens
mRNA and protein samples of human OS tissues (n = 42),
the matched adjacent non-tumor samples (n = 42) and
bone cysts (n = 28) were collected from patients who were
admitted to Shanghai Jiao Tong University Affiliated Sixth
People’s Hospital between 2009 and 2014. The adjacent
non-tumor sample were resected within at least 5 cm of
the tumor margin when the patients underwent definitive
surgery. Pathological white slides of OS tissues and clinical
information were obtained from 18 patients who were
admitted to the cohort. Ethical approval for study was
provided by the ethics committee of Shanghai Jiao Tong
University Affiliated Sixth People’s Hospital. Written
informed consent was obtained from all subjects or their
guardians.
Cell lines and cell culture
U2OS, SoSP-M, SoSP-9607, and MG-63 cells were
purchased from the Cell Bank of China Academy of
Sciences (Shanghai, China) and routinely checked for
Mycoplasma contamination by Hoechst staining. U2OS,
SoSP-M, SoSP-9607 were cultured in RPMI 1640
medium (Gibco, USA) supplemented with 10% fetal
bovine serum (FBS) (Gibco, USA), 10 μg/ml strepto-
mycin sulfate and 100 μg/ml penicillin G. MG-63 cell
lines were cultured in high-glucose Dulbecco’s modified
Eagle’s medium (DMEM; Gibco, USA) supplemented
with 10% fetal bovine serum (FBS) (Gibco, USA),
10 μg/ml streptomycin sulfate and 100 μg/ml penicil-
lin G. Cells were incubated at 37 °C in a humidified
atmosphere containing 5% CO2.
RNA isolation and real-time PCR analysis
Total RNA were extracted from fresh tissues and cells
using TRIzol reagent (Invitrogen, CA, USA) according to
the manufacturer’s protocol. Total RNA (500 ng) was
reverse-transcribed into complementary DNA using the
Reverse Transcription Reagent Kit (TaKaRa, Japan). Real-
time PCR analysis was performed using the 7500 Real-
Time PCR system (Applied Biosystems, USA) with a
SYBR Green PCR Amplification Kit (TaKaRa). Primers are
shown in Table 1. Each PCR analysis was performed in
triplicate, and the results were normalized to β actin ex-
pression. The 2-△△Ct method was used for data analysis.
Western blot analysis
Total proteins were extracted from fresh tissues and
cells using RIPA Protein Lysis solution (Pierce, IL, USA)
and quantified by the Bradford method. Prepared sam-
ples were electrophoresed by sodium dodecyl sulfate
polyacrylamide gel electrophoresis and blotted onto a
polyvinylidene fluoride membrane (Millipore, MA, USA)
using the Tetra Handcast system (Bio-Rad, USA). The
membrane was blocked for 1 h at room temperature or
overnight at 4 °C in Tris-buffered saline with 0.05%
Tween (TBST) containing 5% non-fat milk. Then it was
incubated overnight at 4 °C with the appropriate primary
antibody, and followed by the secondary antibody for
70 min at room temperature. The protein bands were
Table 1 Primers used for the qRT-PCR analysis
genes Sequence (5’-3’)











Snail1 promoter TCAGAAGCGCTCAGACCAC TTATCTGCCACGCCCCTTT
Snail1 non-promoter TGCTCATCTGGGACTCTGTC GAGGAGAAGGACGAAGGAGC
β actin TTGCCGACAGGATGCAGAAG CAGCGAGGCCAGGATGGAGC
Qiu et al. Journal of Experimental & Clinical Cancer Research  (2017) 36:46 Page 2 of 11
detected and quantified using the Gene Gnome Syngene
Bio Imaging System (Syngene, UK) with an electroche-
miluminescence kit (Pierce, IL, USA).
The primary anti-SOX3 antibody was purchased from
Abcam (MA, USA), and the anti-β actin antibody was
purchased from Santa Cruz Biotechnology Inc. (CA,
USA). Other primary antibodies (anti-E-cadherin, anti-
CK-18, anti-N-cadherin, anti-vimentin, anti-Snail1, anti-
Twist1, anti-Slug, anti-ZEB1, anti- ZEB2, anti-FLAG)
were purchased from Cell Signaling Technology (MA,
USA). Anti-mouse or anti-rabbit HRP-conjugated sec-
ondary antibodies were purchase from Santa Cruz
Biotechnology Inc. (CA, USA).
Lentivirus construction, Recombinant plasmid and siRNA
transfection
Lentivirus construction of SOX3-shRNA, control shRNA,
SOX3-overexpression, and control-overexpression were
purchased from Genechem Company (Shanghai, China).
SOX3-targeting shRNA were designed: shRNA-1: 5’- GC
ACATGAAGGAGTATCCGGA-3’; shRNA-2: 5’-GCCGT
GCACATGAAGGAGTAT-3’; shRNA-3: 5’-GACGCTGC
TCAAGAAAGATAA-3’; non-target control shRNA se-
quence: 5’-TTCTCCGAACGTGTCACGT-3’. Stable SO
X3-knockdown and SOX3-upregulation were confirmed
by quantitative real-time PCR and Western Blot analysis.
The plasmids expressed Snail1 and Snail1-siRNA were
purchased from Genechem Company (Shanghai, China).
The small interfering RNA (siRNA) sequence targeting
Snail1 is as follows: 5’-GCGUGGGUUUUUGUAUCC
A(dTdT)-3’. Cells were transfected with plasmid using
Lipofectamine 2000 (Invitrogen) according to the manu-
facturer’s protocol.
Luciferase reporter assays
The Snail1 promoter Luciferase reporter gene was generated
from human genomic DNA corresponding to the sequence
spanning −2,340 to +146 bp (relative to the transcriptional
start site) of the 5’-flanking region of the human Snail1 gene.
Various truncated reporter genes were generated as shown
in Fig. 5. The constructs were confirmed by DNA sequen-
cing. Cells were cultured in 24-well plates and transfected
with 1ug reporter gene construct using Lipofectamine 2000
(Invitrogen) according to the manufacturer’s instructions.
After 24 h of transfection, luciferase activities were mea-
sured using the Dual-Glo™ Luciferase Assay System kit
(Promega, WI, USA). Luciferase intensities were normalized
to the activity of Renilla luciferase.
Chromatin immunoprecipitation assay
We constructed two FLAG-tagged SOX3 variants har-
boring a deletion of the HMG domain or the C-terminal
transcriptional activation domain (SOX3-ΔHMG and
SOX3-ΔCTD). After transfected with the plasmid for
48 h, OS cells were performed with Chromatin immuno-
precipitation assay. OS cells were fixed with 1% formal-
dehyde and processed with the ChIP-IT Enzymatic kit
(Active Motif, Carlsbad, CA) according to the manufac-
turer’s instruction. The resulting protein/DNA com-
plexes were then immuno-precipitated overnight at 4 °C
using anti-Flag antibody (Roche, CH), non-specific IgG
antibodies (Santa Cruz Biotechnology Inc., CA, USA),
respectively, with protein G magnetic beads. After eluted
from beads and incubated with proteinase K, the precip-
itated DNA were amplified and quantified using PCRs.
The primers for Snail1 promoter are shown in Table 1.
Cell migration and matrigel invasion assays
Cell migration was evaluated using the wound-healing
migration assays. Cells were cultured to form a tight cell
monolayer and then wounded with 10 μL plastic pipette
tip. The remaining cells were washed twice with culture
medium to remove cell debris and cultured in normal
serum-containing culture medium with the presence of
Mitomycin C (Amresco) at the concentration of 10 μg/ml.
The incubation is at 37 °C with humidified atmosphere
containing 5% CO2. At the indicated times, migrating
cells at the wound front were photographed. Migration
capacity was quantitated by measuring the percent of
open area in 3–5 randomly captured images.
Cell invasion assays were performed using 24-well
Transwell chambers (8 μm pore size; Millipore) pre-
coated with 100 ul Matrigel (1:7 dilution; BD Biosci-
ences, San Jose, CA, USA). In total, 1 × 105 cells were
suspended in 100 μL serum-free medium with the pres-
ence of mitomycin C (10ug/ml) and were added to the
upper chamber, and 600 μL DMEM that contained 10%
FBS were placed in the lower chamber. After 24 h of in-
cubation, Matrigel and the cells remaining in the upper
chamber were removed by cotton swabs. Cells on the
lower surface of the membrane were fixed in 4% parafor-
maldehyde and stained with crystal violet. Cells at × 200
magnification were counted and photographed. All ex-
periments were performed in triplicate.
In vivo lung metastasis model
The single-cell suspensions of 5×106 OS cells/0.5 ml were
injected into the tail vein of 5-week-old female Nude mice.
The mice were sacrificed at 56 days after injection. The
lungs were resected, and measured by fluorescent areas
measured using the Image-Pro Plus software 6.0 (Media
Cybernetics Inc., Silver Spring, MD, USA).
Immunohistochemistry analysis
Immunohistochemical staining was performed according
to the method of our previous studies [26]. Typically,
after rehydration and antigen retrieval, the slides were
incubated with primary antibodies against SOX3 (1:100,
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Abcam, MA, USA), Snail1(1:100, Cell Signaling Tech-
nology, MA, USA) and E-cadherin (1:100, Cell Signaling
Technology, MA, USA) at 4 °C overnight, followed by
HRP-conjugated secondary antibody at 37 °C for 30 min.
Then the slides were stained with 3,3’-diaminobenzidine
(DAB) and Mayer’s hematoxylin. Immunoreactivity Score
was conducted by two independent observers, who were
blinded to the patients’ information. Five high-power
fields (magnification, 400×) were randomly selected. Based
on the intensity of positive staining, immunoreactivity was
categorized as follows: negative (−), weak (+−), mod-
erate (+), strong (++). Negative and weak correspond
to low expression, moderate and strong correspond to
high expression.
Statistical analysis
Statistical analysis was performed using SPSS16.0 statis-
tical software (SPSS Inc., Chicago, IL, USA). Student’s t-
tests were used to assess significant differences among
study groups. The level of significance was set at p < 0.05.
All experiments were performed at least in triplicate.
Results
SOX3 is upregulated in human OS tissues
We first determined the SOX3 mRNA and protein levels
in 42 cases of human OS tissues and in adjacent non-
tumor samples by qRT-PCR and Western blot analysis.
SOX3 expression was increased in most OS samples
relative to non-tumor samples (Fig. 1a, b). Next, the
SOX3 mRNA level was assessed in OS tissues and bone
cysts (Fig. 1c). SOX3 was overexpressed in most OS
tissues compared with that in bone cysts. We further
evaluated SOX3 expression in various OS cell lines with
different metastatic potential (U2OS, SoSP-M, SoSP-
9607, and MG-63) and the immortal normal osteoblast
cell line, hFOB1.19. SOX3 was expressed at a relatively
higher level in all four OS cell lines compared with
hFOB1.19 (Fig. 1d), suggesting that SOX3 is upregulated
in OS cell lines.
SOX3 promotes OS cell migration and invasion
To explore the role of SOX3 in OS progression, we ex-
amined the effects of SOX3 overexpression or knock-
down on the migratory and invasive abilities of OS cells.
The expression of SOX3 is relatively low in MG63 and
high in U2OS cells. Therefore, we conducted stable
SOX3 overexpression in MG63 cells (MG63-SOX3) and
successful knockdown of SOX3 in U2OS cells (U2OS-
sh-SOX3) (Fig. 2a). Wound-healing migration assays
revealed that MG63-SOX3 cells had an increased rate of
wound closure compared with the MG63-control, and
that U2OS-sh-SOX3 cells had delayed wound closure
compared with the U2OS-sh-control (Fig. 2b). Trans-
well® Matrigel® assays showed that the invasive MG63-
SOX3 cell counts were significantly higher than that
of the control cells and that the invasive U2OS-sh-
SOX3 cell number was decreased compared with the
control (Fig. 2c).
The lung is the most common site of OS metastasis.
Therefore, we used a xenograft nude mouse model to
examine the role of SOX3 expression in lung metastasis in
vivo. We first injected MG63-control and MG63-SOX3
cells into nude mice via the tail vein. After 8 weeks, obvi-
ous lung metastases were detected in the lungs of recipi-
ent mice in the MG63-SOX3 group compared with the
MG63-control group. We then injected U2OS-sh-control
and U2OS-sh-SOX3 cells following the same protocol. As
expected, knockdown of SOX3 significantly reduced lung
metastasis in U2OS-sh-SOX3 cells compared with the
U2OS-sh-control group (Fig. 2d). Therefore, SOX3
appears to play an oncogenic role in OS progression.
SOX3 induces EMT and upregulates Snail1 expression in
OS cells
EMT is the critical process and mechanism by which
local invasion and distant metastasis are initiated. Over-
expression of SOX3 in MG63 cells led to significantly
higher levels of mesenchymal markers (N-cadherin and
vimentin) and lower levels of epithelial markers (E-cad-
herin and Keratin 18) (Fig. 3a, c), whereas knockdown of
SOX3 in U2OS cells caused increased expression of
epithelial markers and decreased expression of mesen-
chymal markers (Fig. 3a, c). These data confirm that
SOX3 induces EMT in OS cells.
To further define the mechanism by which SOX3 regu-
lates EMT, we determined whether SOX3 modulates the
expression of several known EMT-related transcription
factors, including Zeb1, Zeb2, Snail1, Slug, and Twist1.
We determined that the alterations in SOX3 expression
led to significant changes in the expression of Snail1
(Fig. 3b, c), indicating that SOX3 may induce EMT by
enhancing Snail1 expression.
SOX3-promoted EMT is mediated by Snail1
To confirm the involvement of Snail1 in the SOX3-
induced EMT, siRNA targeting Snail1 (siSnail1) was
transfected into MG63-SOX3 cells. siSnail1 partially
abolished the increased migratory and invasive abilities
induced by SOX3 overexpression (Fig. 4a), whereas up-
regulation of Snail1 in U2OS-shSOX3 cells transfected
with a Snail1 plasmid (Snail1) rescued the decreased
cell migration and invasion induced by SOX3 knock-
down (Fig. 4b). Additionally, qRT-PCR and Western
blot analysis demonstrated that the alterations in EMT
markers by SOX3 were reversed by siSnail1 or the
Snail1 plasmid (Fig. 4c, d).
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SOX3 promotes Snail1 transcription via binding to its
promoter region
To explore the mechanism by which SOX3 regulates
Snail1 expression in OS cells, we assessed the SOX3-
dependent regulation of Snail1 mRNA transcription.
The promoter region spanning −2,340 to +146 bp of
Snail1 was used in a luciferase reporter assay. MG63-
control and MG63-SOX3 cells were transfected with the
reporter gene. SOX3 overexpression in MG63 cells pro-
moted the reporter activity of Snail1 (Fig. 5c). Sequence
analyses of the Snail1 promoter region showed three
putative SOX3-binding sites (Fig. 5a, b). To determine
the cis-regulatory elements of the Snail1 promoter in re-
sponse to SOX3 regulation, various truncated reporter
genes were constructed (Fig. 5c). SOX3 overexpression
affected the transactivation of the shortest construct
containing only the third binding site promoter se-
quence (−651 to +146 bp), while the deletion of sites 1
and 2 had no significant effect on SOX3-regulated Snail1
promoter activity. The deletion or substitution of site 3
showed notable inhibition of Snail1 promoter activity,
suggesting that site 3 is the critical core binding site of
SOX3 (Fig. 5c).
SOX3 contains a DNA-binding HMG domain and a
C-terminal transcriptional activation domain. To deter-
mine the region required for its ability to transactivate
Snail1 mRNA, we constructed two FLAG-tagged SOX3
variants harboring a deletion of the HMG domain or the
C-terminal transcriptional activation domain (SOX3-
ΔHMG and SOX3-ΔCTD, respectively) and performed a
chromatin immunoprecipitation (ChIP) assay. SOX3-
WT and SOX3-ΔCTD, but not SOX3-ΔHMG, pulled
down the promoter region but not the non-promoter
region of the Snail1 gene (Fig. 5d, e). These data demon-
strate that the HMG domain is critical for SOX3-
activated Snail1 expression.
SOX3 expression correlates with that of Snail1 and E-
cadherin in human OS tissues
We next assessed the relationships between SOX3, Snail1,
and E-cadherin expression by immunohistochemistry in
18 human OS tissues. Twelve OS tissues exhibited high
Fig. 1 SOX3 is upregulated in human osteosarcoma tissues. a, b Relative SOX3 mRNA and protein levels were significantly increased in osteosarcoma
tissues when compared with the adjacent non-tumor tissues (n = 42). c Relative SOX3 mRNA level was significantly higher in osteosarcoma tissues
(n = 42) than that in bone cysts (n = 28). d, e SOX3 mRNA and protein levels in different OS cell lines. Data represent the mean ± SD of triplicate
samples; *P < 0.05, **P < 0.01
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expression of SOX3; 6 had low expression. Nine of 12 tu-
mors with high SOX3 expression tended to have higher
Snail1 levels and seven showed lower E-cadherin levels
(Table 2). In contrast, 4 of 6 tumors with low SOX3
expression exhibited lower Snail1 expression and 5 exhib-
ited higher E-cadherin expression (Table 2). These data
suggest that SOX3 expression positively correlates with
that of Snail1 and negatively correlates with E-cadherin
(Fig. 6a). Additionally, correlation analysis between the
mRNA expression of SOX3, Snail1, and E-cadherin in 42
OS tissues also show the similar results (Fig. 6b). We also
analyzed the relationship between SOX3 and the clinical
pathological characteristic (Table 2). However, there were
no significant statistically.
Discussion
SOX3 is a member of the SOX family of transcription
factors that plays important roles in the regulation of
embryonic development and in the determination of cell
fate [17, 19, 20]. Recent studies have reported that SOX3
is linked to various cancers, including esophageal squamous
cell carcinoma, ovarian cancer, and T-cell lymphomas
[22, 23, 25]. In the present study, we first demon-
strated that SOX3 was expressed at a higher level in
OS tissues compared with normal tissues. In vivo and in
vitro experiments suggested that SOX3 promoted OS cell in-
vasion and metastasis. Further analysis showed that SOX3
significantly induced EMT by promoting Snail1 expression.
Moreover, a positive correlation between SOX3 and Snail1
Fig. 2 SOX3 promotes OS cell migration and invasion. a SOX3 overexpression in MG63 cells and successful knockdown of SOX3 in U2OS cells were
confirmed by western blot and qRT-PCR. b Wound-healing migration assays and the distance quantification of wound closure. c The invasive OS cells
and quantitation of invasive OS cell counts. d The lung metastatic foci were photographed. Representative views of lung tissue section are shown. The
results are expressed as the mean ± SD of triplicate samples; * P < 0.05, **P < 0.01
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Fig. 3 SOX3 induces EMT and upregulates Snail1 expression. a qRT-PCR shows changes of EMT marker expression affected by SOX3 upregulation
and downregulation. b qRT-PCR shows changes of EMT-related transcription factors expression affected by SOX3 upregulation and downregulation.
c western blot shows the protein expression of EMT markers and related transcription factors. The results are expressed as the mean ± SD of triplicate
samples; * P < 0.05, **P < 0.01
Fig. 4 SOX3-induced EMT is mediated by Snail1 transcription factor. a siRNA against Snail1 abolished the increased cell ability of migration and
invasion produced by SOX3 overexpression. b Snail1 plasmid (Snail1) significantly rescued the decreased cell migration and invasion produced by
SOX3 knockdown. c, d the alterations of EMT markers by SOX3 were also reversed by siSnail1 or Snail1 plasmid. The results are expressed as the
mean ± SD of triplicate samples; * P < 0.05, **P < 0.01
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expression was validated in OS samples. These data suggest
that SOX3 plays a crucial role in OS progression.
Cancer has been proposed to have six fundamental hall-
marks [27], which include self-sufficiency in growth factors,
insensitivity to growth-inhibitory signals, evasion of apop-
tosis, limitless replicative potential, sustained angiogenesis,
and the ability to invade and metastasize. The primary
tumor is rarely fatal to the organism. It is the final hallmark
of cancer, invasion and metastasis, which underlies its
deadly progressive nature [27]. Metastatic spread is respon-
sible for more than 90% of all cancer-related deaths, yet,
despite this being well-known, metastasis in and of itself re-
mains the most poorly understood component of cancer
progression. OS is also characterized by a high propensity
for metastasis (especially to the lung), which is the leading
cause of death [1]. Our study revealed a crucial role for
SOX3 in promoting OS invasion and metastasis both in
vitro and in vivo, strongly suggesting that SOX3 may serve
as a therapeutic target for patients with metastatic OS.
EMT is a key event in the tumor invasion and metastasis
process that enables epithelial cells to acquire an invasive
mesenchymal phenotype. EMT is characterized by a loss
of intercellular adhesion (E-cadherin), downregulation of
epithelial makers (cytokeratins), upregulation of mesen-
chymal markers (vimentin), acquisition of a spindle-like
morphology, and an increase in motility, invasiveness, and
metastatic capabilities [6]. In addition, the process known
as “cadherin switching” (downregulation of E-cadherin
and upregulation of mesenchymal cadherins such as N-
cadherin [28]) and the accumulation of β-catenin have
also been associated with EMT [29]. Previous studies have
revealed the increased EMT characteristics in OS cells and
Fig. 5 SOX3 promotes Snail1 transcription via binding to the promoter region. a Sequence logo of SOX3 from JASPAR database. b Three putative
SOX3-binding sites in Snail1 promoter region. c Truncation analysis of the Snail1 reporters. Five kinds of reporters, including upstream regions
from bp −2340, −1267, −651 to bp +146, and upstream regions with site 3 deletion or site 3 substitution, were analyzed for their activity.
(d, e) FLAG-tagged SOX3 variants (SOX3-ΔHMG and SOX3-ΔCTD) were followed by chromatin immunoprecipitation (ChIP) assay. Precipitated
DNAs were quantified by qRT-PCR for promoter and non-promoter regions of Snail1 gene. The results are expressed as the mean ± SD of triplicate
samples; * P < 0.05, **P < 0.01
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demonstrated the involvement of EMT in OS invasiveness
and migration [30–33]. In our study, the decreased inva-
sive ability of the U2OS cell line induced by the depletion
of SOX3 prompted us to investigate whether SOX3 is in-
volved in EMT. As expected, SOX3 silencing upregulated
epithelial markers, such as E-cadherin, and downregulated
mesenchymal markers, such as N-cadherin and vimentin.
Consistent with these data, ectopic expression of SOX3 in
MG63 cells led to opposing results. This involvement of
SOX3 in regulating EMT provided an explanation for the
increased levels of SOX3 expression promoting OS cell
invasiveness and metastasis.
EMT is a very complex process that is executed in
response to pleiotropic signaling factors that include sev-
eral transcriptional repressors, such as Snail1, Snail2, Zeb1,
Zeb2, and Twist. The roles of these factors in promoting
invasiveness and metastasis have been widely reported
[34–38]. However, the upstream mechanism of these tran-
scriptional repressors in cancer progression are still elusive.
Previous studies revealed that SOX family of proteins play
important role in cancer development [39–41]. For ex-
ample, SOX5 promoted EMT process by regulation of
Twist1 in hepatocellular carcinoma [41]. These literatures
give us an implication that SOX3, as a member of SOX
family, might play the potential role in regulating EMT-
related transcriptional factors. Therefore, our study
investigated the hypothesis and demonstrated that
SOX3 enhanced Snail1 expression via binding to the
site 3 region of the Snail1 promoter, thereby inducing
EMT and promoting OS cell invasion and metastasis.
Previous studies have reported that SOX3 is correlated
with the development of several types of cancer, including
esophageal squamous cell carcinoma, ovarian cancer, and
T-cell lymphomas, and induces oncogenic transformation
of chicken embryonic fibroblasts [22, 23, 25]. These find-
ings, together with our results showing that SOX3 is dra-
matically overexpressed in OS tissues and promotes OS cell
invasion and metastasis, suggest that SOX3 may act as an
oncogene. However, before defining SOX3 as an oncogene
in OS progression, the relationship between SOX3 expres-
sion and the prognosis, pathology, and clinical phenotype
of patients with OS should be investigated. Our studies
showed that there was no significant relationship between
SOX3 expression and the clinical pathological features in
18 patients with OS. This might be related to the limited
sample size. The collection of a larger number of samples
and clinical information is currently underway.
Conclusion
In conclusion, the collective findings from our study show
for the first time that SOX3 acts as a metastasis-associated
gene in OS. The mechanistic link among SOX3, Snail1,
and EMT indicates SOX3 as a potential therapeutic target
for OS metastasis.
Table 2 The relationship between SOX3 expression and
clinicopathological features OS
Clinicopathological features SOX3 P value
Low High
Age (y) ≤20 3 8 0.494125
>20 3 4
Gender Male 4 7 0.73244
Female 2 5
Grade Grade1 2 2 0.637628
Grade2 3 6
Grade3 1 4
Metastasis Yes 2 6 0.502335
No 4 6
5-year survival Absent 1 5 0.288844
Present 5 7
Snail1 Low 4 3 0.087375
High 2 9
E-cadherin Low 1 7 0.093533
High 5 5
Fig. 6 Correlation between the expression of SOX3 and Snail1, E-cadherin
in patients with osteosarcoma. a The expression level of SOX3 by
immunohistochemistry in 68 patients’ osteosarcoma tissues. b Correlation
analysis between the expression of SOX3 and Snail1, E-cadherin
Qiu et al. Journal of Experimental & Clinical Cancer Research  (2017) 36:46 Page 9 of 11
Abbreviations
ChIP: Chromatin immunoprecipitation; CK-18: Keratin 18; CSC: Cancer stem
cell; EMT: Epithelial-mesenchymal transition; EMT-TFs: Transcription factors
associated with EMT; OS: Osteosarcoma; qRT-PCR: Quantitative real-time poly-
merase chain reaction; siSnail1: siRNA targeting Snail1; SOX3: Sex-




This study was sponsored by grants from the National Natural Science
Foundation of China (No. 81271998) and the National High-Tech Research
and development program (863-Project, No. 2015AA020316).
Availability of data and materials
Not applicable.
Authors’ contributions
YH and MQ conceived and designed the study. MQ, DC, CS performed the
experiments. JS, HZ analyzed the data. All authors read and approved the
final manuscript.
Competing interests
All authors have no conflicts of interest to disclose.
Consent for publication
Informed consent for publication was obtained from all subjects or their
guardians.
Ethics approval and consent to participate
Ethical approval for study was provided by the ethics committee of
Shanghai Jiao Tong University Affiliated Sixth People’s Hospital. Written
informed consent was obtained from all subjects or their guardians.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Sports Medicine, Shanghai Jiao Tong University Affiliated
Sixth People’s Hospital, 600 Yishan Road, Shanghai 200233, China.
2Department of Gastrointestinal Surgery, West China Hospital, Sichuan
University, Chengdu 610041, Sichuan, China.
Received: 18 January 2017 Accepted: 11 March 2017
References
1. Jaffe N. Osteosarcoma: review of the past, impact on the future, The
American experience. Cancer Treat Res. 2009;152:239–62.
2. Palmerini E, Fabbri N, Staals EL, Marchesi E, Alberghini M, Tienghi A, Fagioli
F, Picci P, Mercuri M, Ferrari S. Osteosarcoma of the pelvis and sacrum: a
retrospective analysis of 73 patients. J Clin Oncol. 2011;29(15_suppl):10039.
3. Hegyi M, Semsei AF, Jakab Z, Antal I, Kiss J, Szendroi M, Csoka M, Kovacs G.
Good prognosis of localized osteosarcoma in young patients treated with
limb-salvage surgery and chemotherapy. Pediatr Blood Cancer. 2011;57(3):
415–22.
4. Mialou V, Philip T, Kalifa C, Perol D, Gentet JC, Marec-Berard P, Pacquement
H, Chastagner P, Defaschelles AS, Hartmann O. Metastatic osteosarcoma at
diagnosis: prognostic factors and long-term outcome–the French pediatric
experience. Cancer Am Cancer Soc. 2005;104(5):1100–9.
5. Zavadil J, Haley J, Kalluri R, Muthuswamy SK, Thompson E. Epithelial-
mesenchymal transition. Cancer Res. 2008;68(23):9574–7.
6. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal
transitions in development and disease. Cell. 2009;139(5):871–90.
7. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal
transition: new insights in signaling, development, and disease. J Cell Biol.
2006;172(7):973–81.
8. Larsen JE, Nathan V, Osborne JK, Farrow RK, Deb D, Sullivan JP, Dospoy PD,
Augustyn A, Hight SK, Sato M, Girard L, Behrens C, Wistuba II, Gazdar AF,
Hayward NK, Minna JD. ZEB1 drives epithelial-to-mesenchymal transition in
lung cancer. J Clin Invest. 2016;126(9):3219–35.
9. Gao Y, Xuan XY, Zhang HY, Wang F, Zeng QR, Wang ZQ, Li SS. Relationship
between TWIST expression and epithelial–mesenchymal transition of
oesophageal squamous cell carcinoma. Cell Biol Int. 2012;36(6):571–7.
10. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition.
J Clin Invest. 2009;119(6):1420–8.
11. Ru N, Liang J, Zhang F, Wu W, Wang F, Liu X, Du Y. SPRY4 intronic transcript
1 promotes Epithelial-mesenchymal transition through association with
Snail1 in Osteosarcoma. DNA Cell Biol. 2016;35(6):290–5.
12. Robson EJ, Khaled WT, Abell K, Watson CJ. Epithelial-to-mesenchymal
transition confers resistance to apoptosis in three murine mammary
epithelial cell lines. Differentiation. 2006;74(5):254–64.
13. Vega S, Morales AV, Ocana OH, Valdes F, Fabregat I, Nieto MA. Snail blocks
the cell cycle and confers resistance to cell death. Genes Dev. 2004;18(10):
1131–43.
14. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions.
J Clin Invest. 2009;119(6):1429–37.
15. Canesin G, Cuevas EP, Santos V, Lopez-Menendez C, Moreno-Bueno G,
Huang Y, Csiszar K, Portillo F, Peinado H, Lyden D, Cano A. Lysyl oxidase-like
2 (LOXL2) and E47 EMT factor: novel partners in E-cadherin repression and
early metastasis colonization. Oncogene. 2015;34(8):951–64.
16. Vidal B, Santella A, Serrano-Saiz E, Bao Z, Chuang CF, Hobert O. C. elegans
SoxB genes are dispensable for embryonic neurogenesis but required for
terminal differentiation of specific neuron types. Development. 2015;142(14):
2464–77.
17. Vetro A, Dehghani MR, Kraoua L, Giorda R, Beri S, Cardarelli L, Merico M,
Manolakos E, Parada-Bustamante A, Castro A, Radi O, Camerino G, Brusco A,
Sabaghian M, Sofocleous C, Forzano F, et al. Testis development in the
absence of SRY: chromosomal rearrangements at SOX9 and SOX3.
Eur J Hum Genet. 2015;23(8):1025–32.
18. Bell DM, Leung KK, Wheatley SC, Ng LJ, Zhou S, Ling KW, Sham MH,
Koopman P, Tam PP, Cheah KS. SOX9 directly regulates the type-II collagen
gene. Nat Genet. 1997;16(2):174–8.
19. Fu L, Shi YB. The Sox transcriptional factors: Functions during intestinal
development in vertebrates. Semin Cell Dev Biol. 2016.
20. Yin C. Molecular mechanisms of Sox transcription factors during the
development of liver, bile duct, and pancreas. Semin Cell Dev Biol. 2017;63:
68–78.
21. Uwanogho D, Rex M, Cartwright EJ, Pearl G, Healy C, Scotting PJ and
Sharpe PT. Embryonic expression of the chicken Sox2, Sox3 and Sox11
genes suggests an interactive role in neuronal development. Mech Dev.
1995;49:23–36.
22. Li K, Wang RW, Jiang YG, Zou YB, Guo W. Overexpression of Sox3 is
associated with diminished prognosis in esophageal squamous cell
carcinoma. Ann Surg Oncol. 2013;20 Suppl 3:S459–66.
23. Yan Q, Wang F, Miao Y, Wu X, Bai M, Xi X, Feng Y. Sex-determining region
Y-box3 (SOX3) functions as an oncogene in promoting epithelial ovarian
cancer by targeting Src kinase. Tumour Biol. 2016;37(9):12263–71.
24. Kim R, Trubetskoy A, Suzuki T, Jenkins NA, Copeland NG, Lenz J. Genome-
based identification of cancer genes by proviral tagging in mouse
retrovirus-induced T-cell lymphomas. J Virol. 2003;77(3):2056–62.
25. Xia Y, Papalopulu N, Vogt PK, Li J. The oncogenic potential of the high
mobility group box protein Sox3. Cancer Res. 2000;60(22):6303–6.
26. Dong Y, Shen X, He M, Wu Z, Zheng Q, Wang Y, Chen Y, Wu S, Cui J, Zeng
Z. Activation of the JNK-c-Jun pathway in response to irradiation facilitates
Fas ligand secretion in hepatoma cells and increases hepatocyte injury.
J Exp Clin Cancer Res. 2016;35(1):114.
27. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell.
2011;144(5):646–74.
28. Yao D, Dai C, Peng S. Mechanism of the mesenchymal-epithelial transition
and its relationship with metastatic tumor formation. Mol Cancer Res. 2011;
9(12):1608–20.
29. Gheldof A, Berx G. Cadherins and epithelial-to-mesenchymal transition.
Prog Mol Biol Transl Sci. 2013;116:317–36.
30. Xu G, Guo Y, Xu D, Wang Y, Shen Y, Wang F, Lv Y, Song F, Jiang D, Zhang
Y, Lou Y, Meng Y, Yang Y, Kang Y. TRIM14 regulates cell proliferation and
invasion in osteosarcoma via promotion of the AKT signaling pathway. Sci
Rep. 2017;7:42411.
31. Lv YF, Dai H, Yan GN, Meng G, Zhang X, Guo QN. Downregulation of tumor
suppressing STF cDNA 3 promotes epithelial-mesenchymal transition and
Qiu et al. Journal of Experimental & Clinical Cancer Research  (2017) 36:46 Page 10 of 11
tumor metastasis of osteosarcoma by the Wnt/GSK-3beta/beta-catenin/Snail
signaling pathway. Cancer Lett. 2016;373(2):164–73.
32. Guo X, Zhang J, Pang J, He S, Li G, Chong Y, Li C, Jiao Z, Zhang S, Shao M.
MicroRNA-503 represses epithelial-mesenchymal transition and inhibits
metastasis of osteosarcoma by targeting c-myb. Tumour Biol. 2016;37(7):9181–7.
33. Liu X, Liang Z, Gao K, Li H, Zhao G, Wang S, Fang J. MicroRNA-128 inhibits
EMT of human osteosarcoma cells by directly targeting integrin alpha2.
Tumour Biol. 2016;37(6):7951–7.
34. Zhou ZJ, Dai Z, Zhou SL, Hu ZQ, Chen Q, Zhao YM, Shi YH, Gao Q, Wu WZ,
Qiu SJ, Zhou J and Fan J. HNRNPAB Induces Epithelial-Mesenchymal
Transition and Promotes Metastasis of Hepatocellular Carcinoma by
Transcriptionally Activating SNAIL. Cancer Res. 2014;74(10):2750–62.
35. Sung JY, Park SY, Kim JH, Kang HG, Yoon JH, Na YS, Kim YN, Park BK.
Interferon consensus sequence-binding protein (ICSBP) promotes epithelial-
to-mesenchymal transition (EMT)-like phenomena, cell-motility, and invasion
via TGF-beta signaling in U2OS cells. Cell Death Dis. 2014;5:e1224.
36. Liu C, Lin J. Long noncoding RNA ZEB1-AS1 acts as an oncogene in
osteosarcoma by epigenetically activating ZEB1. Am J Transl Res. 2016;8(10):
4095–105.
37. Li M, Chen H, Zhao Y, Gao S, Cheng C. H19 Functions as a ceRNA in
Promoting Metastasis Through Decreasing miR-200 s Activity in
Osteosarcoma. DNA Cell Biol. 2016;35(5):235–40.
38. Lei P, Ding D, Xie J, Wang L, Liao Q, Hu Y. Expression profile of Twist,
vascular endothelial growth factor and CD34 in patients with different
phases of osteosarcoma. Oncol Lett. 2015;10(1):417–21.
39. Inoue H, Takahashi H, Hashimura M, Eshima K, Akiya M, Matsumoto T,
Saegusa M. Cooperation of Sox4 with beta-catenin/p300 complex in
transcriptional regulation of the Slug gene during divergent sarcomatous
differentiation in uterine carcinosarcoma. BMC Cancer. 2016;16:53.
40. Pei X, Lv X, Li H. Sox5 induces epithelial to mesenchymal transition by
transactivation of Twist1. Biochem Bioph Res Co. 2014;446(1):322–7.
41. Wang D, Han S, Wang X, Peng R, Li X. SOX5 promotes epithelial-
mesenchymal transition and cell invasion via regulation of Twist1 in
hepatocellular carcinoma. Med Oncol. 2015;32(2):461.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Qiu et al. Journal of Experimental & Clinical Cancer Research  (2017) 36:46 Page 11 of 11
